CGRP supplementation prevents cognitive decline by rescuing microvascular constriction in chronic brain hypoperfusion | Research

The takeaway

In a rat model of vascular cognitive impairment, vasoactive neuropeptide dysregulation (especially CGRP depletion) drives microvascular constriction as the primary pathological event, preceding amyloid accumulation, with CGRP supplementation preventing vasoconstriction and improving cognition.

CGRP depletion drives dementia
Vasoactive neuropeptide dysregulation—not amyloid—is the primary driver of vascular cognitive impairment, with CGRP supplementation preventing cognitive decline

What the researchers found

Vasoactive neuropeptide dysregulation = primary VCI driver. Microvascular constriction: earliest event, precedes amyloid. CGRP depletion: key driver. CGRP supplementation: prevented vasoconstriction + improved cognition. Capillary constriction precedes and drives amyloid accumulation.

Why it matters

This reverses conventional thinking: microvascular damage driven by neuropeptide dysregulation may CAUSE amyloid accumulation (not the other way around), with CGRP supplementation as a potential therapeutic approach for vascular dementia.

How the study worked

Chronic cerebral hypoperfusion rat model. Proteomic analysis. Neuropeptide and non-neuropeptide marker evaluation across VCI severities. Cognitive testing. CGRP supplementation experiments.

What this study cannot tell us

Rat model. CGRP supplementation method not detailed. Human VCI pathophysiology may differ. Proteomic findings need independent validation.

How to read the evidence

Proteomics-guided preclinical study with therapeutic validation. Novel finding challenging established paradigms.

When this study was published

Published in 2025.

The bigger picture

This challenges the amyloid-centric view of cognitive decline. If microvascular neuropeptide dysfunction drives both vascular damage and amyloid accumulation, targeting CGRP could prevent both forms of dementia simultaneously.

Questions still open

Could CGRP agonists prevent dementia in humans with cerebrovascular risk?
Does this mean anti-CGRP migraine drugs could worsen cognitive function?
Is CGRP depletion measurable in at-risk patients as a biomarker?

Common questions

Could CGRP prevent dementia?

This groundbreaking study suggests yes. In rats with reduced brain blood flow (mimicking vascular dementia), CGRP depletion was the primary driver of cognitive decline—and supplementing CGRP prevented both blood vessel constriction and cognitive impairment. Importantly, this happened BEFORE amyloid accumulation, suggesting CGRP loss drives the disease process.

Should migraine patients on anti-CGRP drugs be concerned about their brain?

This raises an important question. If CGRP protects brain blood vessels and cognition, blocking it for migraine might theoretically affect long-term brain health. However, anti-CGRP drugs primarily act peripherally and may not significantly deplete brain CGRP. This needs careful long-term monitoring in migraine patients.

Read the original research

Vasoactive neuropeptide dysregulation: A novel mechanism of microvascular dysfunction in vascular cognitive impairment.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 21(11), e70925

View on PubMed ↗Publisher’s paper ↗

Citation

Tambo, Willians; Powell, Keren; Wadolowski, Steven; Unadkat, Prashin; Chang, Eric H; LeDoux, Christopher; Sciubba, Daniel; Wang, Ping; Huerta, Patricio; Li, Chunyan. (2025). Vasoactive neuropeptide dysregulation: A novel mechanism of microvascular dysfunction in vascular cognitive impairment.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 21(11), e70925. https://doi.org/10.1002/alz.70925